A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048).

Trial Profile

A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Brivanib alaninate (Primary)
  • Indications Adenocarcinoma; Carcinoma; Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jul 2017 Status changed from suspended to discontinued as per results published in the Gynecologic Oncology
    • 17 Jul 2017 Results published in the Gynecologic Oncology
    • 17 Jun 2017 Primary endpoint (Progression-Free Survival) has been met as per the results published in the Gynecologic Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top